Anti-B. anthracis anthrax protective antigen (Panobacumab) (CAT#: TAB-105)

Figure 1 Reduced lung inflammation after Panobacumab treatment in immunosuppressed P. aeruginosa-infected mice.

B6 mice were immunosuppressed with cyclophosphamide (100 mg/kg) and 3 days later infected by intra-nasal instillation of 40 µL of P. aeruginosa strain 2310.55 (2x105 cfu). Panobacumab was given i.v. at 0.4 mg/kg, 4 h after the infection. Absolute numbers of cells (A), neutrophils (B) were measured in BALF 24 h after infection. Lung MPO (C) was recorded 24 h after infection. The concentrations of IL-6 (D) and IL-1β (E) in lung homogenates were determined 24 h after infection. Groups of 8-10 mice were used and mean values ± SEM are shown (One-way ANOVA with Tukey's Multiple Comparison Test: * p<0.05, *** p<0.001). The results are a pool of two independent experiments.

Secher, T., Fas, S., Fauconnier, L., Mathieu, M., Rutschi, O., Ryffel, B., & Rudolf, M. (2013). The anti-Pseudomonas aeruginosa antibody Panobacumab is efficacious on acute pneumonia in neutropenic mice and has additive effects with meropenem. PloS one, 8(9), e73396.